Beijing Hospital
Beijing, Beijing Municipality, China
NCT Number: NCT07156500
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of HS-20094 injection in subjects with type 2 diabetes who have inadequate glycemic control with diet and exercise alone. The primary objective of this study is to evaluate the effectiveness of HS-20094 compared to placebo in controlling blood glucose levels after 44 weeks and 52 weeks treatment.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 3
Beijing, Beijing Municipality, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HS-20094 injected subcutaneously once weekly
HS-20094 Placebo injected subcutaneously once weekly
Time frame: Week 0 to Week 44
Change from baseline in HbA1c after 44 weeks of treatment
Time frame: Week 0 to Week 44
Proportion of subjects with HbA1c<7.0% and ≤6.5% after 44 weeks of treatment
Time frame: Week 0 to Week 44
Change from baseline in FPG after 44 weeks of treatment
Time frame: Week 0 to Week 44
Change from baseline in Change in body weight after 44 weeks of treatment
Time frame: Week 0 to Week 44
Proportion of subjects with weight loss ≥5% and ≥10% after 44 weeks of treatment
Time frame: Week 0 to Week 52
Change from baseline in HbA1c after 52 weeks of treatment
Time frame: Week 0 to Week 52
Proportion of subjects with HbA1c<7.0% and ≤6.5% after 52 weeks of treatment
Time frame: Week 0 to Week 52
Change from baseline in FPG after 52 weeks of treatment
Time frame: Week 0 to Week 52
Change from baseline in Change in body weight after 52 weeks of treatment
Time frame: Week 0 to Week 52
Proportion of subjects with weight loss ≥5% and ≥10% after 52 weeks of treatment
Time frame: Week 0 to Week 52+4 weeks follow-up
Severity (mild, moderate and severe) is assessed by investigator
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Industry
A Multicenter, Randomized, Double-Blind, Placebo- Parallel Controlled, Phase III Study to Evaluate the Efficacy and Safety of HS-20094 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07736040
Diabetes Mellitus, Diabetes Mellitus, Type 2
View Trial DetailsNCT07718867
Diabetes Mellitus, Diabetes Mellitus, Type 2
Dali, Yunnan, China
View Trial DetailsNCT07726589
Behavior, Diabetes Complications
Taipei, Zhongzheng District, Taiwan
View Trial DetailsNCT07605390
Albuminuria, Chronic Disease
Dallas, Texas, United States
View Trial Details